Tolerability and efficacy of a medical device repairing emollient cream in adults with chronic hand dermatitis
Summary Background Emollients are recommended for managing chronic hand dermatitis (CHD). Medical device repairing emollient creams (MDRECs) are suitable for treating CHD‐associated skin lesions, unlike most cosmetic emollient products that can only be used on healthy skin. Objectives The aim of thi...
Saved in:
Published in | Journal of cosmetic dermatology Vol. 17; no. 6; pp. 1158 - 1164 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
01.12.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 1473-2130 1473-2165 1473-2165 |
DOI | 10.1111/jocd.12764 |
Cover
Summary: | Summary
Background
Emollients are recommended for managing chronic hand dermatitis (CHD). Medical device repairing emollient creams (MDRECs) are suitable for treating CHD‐associated skin lesions, unlike most cosmetic emollient products that can only be used on healthy skin.
Objectives
The aim of this study was to examine the tolerability and benefit of a MDREC, Dexyane MeD®, in adults with CHD.
Methods
In an open‐label study, adults aged 18‐65 years with mild‐to‐moderate CHD were instructed to apply the MDREC on both hands twice daily for 3 weeks. Investigators assessed tolerability and CHD severity on days 1, 8, and 22. Subjects assessed CHD severity weekly and completed the Dermatology Life Quality Index on days 1, 8, and 22. Differences from baseline were compared by Wilcoxon matched‐pairs signed‐rank test or paired t test. Satisfaction with the MDREC was assessed by subjects.
Results
Forty subjects were included and completed the study. Tolerability was good to excellent for all subjects. Subjects and investigators reported decreased severity of CHD at days 8 and 22 compared with Day 1 (P < 0.001), and subjects reported decreased pain and pruritus (P < 0.001). Quality of life improved, and most subjects were satisfied with the MDREC's characteristics and application.
Conclusions
The MDREC was well tolerated and may help manage mild‐to‐moderate CHD. |
---|---|
Bibliography: | Funding information This study was funded by Pierre Fabre Dermo‐Cosmétique Laboratories, France. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 1473-2130 1473-2165 1473-2165 |
DOI: | 10.1111/jocd.12764 |